US 11,717,509 B2
Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
Chan Mi Joung, Gyeonggi-do (KR); Sun Gwan Hwang, Gyeonggi-do (KR); Ji Won Lee, Gyeonggi-do (KR); and Young Koo Jang, Gyeonggi-do (KR)
Assigned to SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-do (KR)
Filed by SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-do (KR)
Filed on Aug. 9, 2021, as Appl. No. 17/397,177.
Application 17/397,177 is a continuation of application No. 16/763,604, granted, now 11,116,751, previously published as PCT/KR2018/013769, filed on Nov. 13, 2018.
Claims priority of application No. 10-2017-0151253 (KR), filed on Nov. 14, 2017.
Prior Publication US 2021/0361622 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/41 (2006.01); A61K 31/496 (2006.01)
CPC A61K 31/41 (2013.01) [A61K 31/496 (2013.01)] 17 Claims
 
1. A combination comprising (a) a carbamate compound of the following Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof; and (b) an antipsychotic agent selected from the group consisting of asenapine, clozapine, iloperidone, olanzapine, lurasidone, paliperidone, quetiapine, risperidone, ziprasidone, and a pharmaceutically acceptable salt, solvate or hydrate thereof:

OG Complex Work Unit Chemistry
wherein,
R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 thioalkoxy and C1-C8 alkoxy; and
one of A1 and A2 is CH, and the other is N.